Breaking News

Innate Pharma to License Antibodies to Takeda for Celiac Disease Research Program

Takeda will be responsible for the future development, manufacture and commercialization of any potential products.

Innate Pharma SA entered into an exclusive license agreement with Takeda under which Innate grants Takeda exclusive worldwide rights to research and develop antibody drug conjugates (ADC) using a panel of selected Innate antibodies against an undisclosed target, with a primary focus in Celiac disease.   Takeda will be responsible for the future development, manufacture and commercialization of any potential products developed using the licensed antibodies. Innate will receive a $5 million u...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters